15 Stocks Having ATough Quarter But Worth A Look

Mon, 21 Sep 2009 05:06:38 GMT

The S&P 500 ended moved into the green in May and has never looked back. So far in Q3, it's up a whopping 16.8%, even better than Q2's 15.9% total return. Despite the large advance, 40 of the members are actually down QTD. Thinking that there might be some opportunities from the long side, I wanted to take a closer look, so I created a screen in StockVal to narrow the list. Here is how I constrained the group:[More...]

Q2 Growth Report - Part 1

Tue, 01 Sep 2009 03:48:21 GMT

Today's Wall Street Journal had an article that asked the question "Can Rally Run without Revenue?" Is the revenue situation really that bad? Let's take a quick look at some the data compiled through the Alert HQ process. After each quarter's earnings season, I try to pull together what I am now calling the Growth Report. Part 1 compiles the list of stocks that have shown a year-over-year increase in both revenue and earnings AND a sequential quarter-over-quarter increase in both revenue and earnings. Given the severity of the economic downturn, very few companies have been able to to pull off this trick. The following table presents a comparison of the last two quarters: [More...]

Earnings Season Is Over - Who Were The Growth Leaders?

Tue, 19 May 2009 03:27:49 GMT

Earnings season is pretty much over now. Many companies managed to beat drastically reduced expectations. As a result, many bears focused on poor earnings quality and the fact that the bar had been lowered so far, it was no great accomplishment to exceed expectations. There were a number of stocks, though, that beat fair and square. We compiled a list of stocks that had increased earnings per share sequentially and year-over-year and increased revenues sequentially and year-over-year. We had 218 stocks that made the list. We then cross referenced this list with the S&P 500 and came up with the following list of 27 stocks: SymbolNameAETAETNA[More...]

Quest Diagnostics (NYSE:DGX): Added To Conviction Sell List At Goldman Sachs

Fri, 06 Mar 2009 13:23:00 GMT

Goldman Sachs is adding Quest Diagnostics (NYSE:DGX) to Conviction Sell list while lowering their tgt to $38 from $45. Downside to DGX on valuation, volumes and health reform Following relative outperformance since 4Q08, they expect Quest shares will underperform their coverage, with valuation at risk of market-relative convergence to other healthcare services names. DGX’s >10% premium to peer LH (7.1x vs 6.2x EV/EBITDA) is not justified given less balance sheet flexibility; in addition, they’ve highlighted downside risk to its outlook for 3% revenue growth this year in light of macroeconomic trends. Finally, the firm highlights potential downside to Medicare lab reimbursement as healthcare reform discussions advance (esp. given emerging pressure in the[More...]

Obama-Care Focused on Preventive Medicine

Wed, 05 Nov 2008 23:15:00 GMT

In addition to bullish outlooks for generic drugs and Health IT, President-Elect Obama's healthcare plan plans to focus on public health initiatives and mandated coverage of preventive services such as cancer screenings. The accompanying table presents statistics and the top five rated companies in[More...]

Virtual Funds: Healthcare Fund's Ranking/Performance In Q3 '08 And Overall

Sat, 01 Nov 2008 17:26:00 GMT

Among all the sectors, healthcare has held up better than most. Of course, now, with the benefit of hindsight, various pundits and talking heads are pointing out that this is the safe haven with a lot of growth potential. What's the logic here? Since this sector has lost the least, it must grow the most now? Nonsense. If anything, now is probably not the time to invest in the healthcare considering the significance of upside potential in other, very beaten-down sectors. If you're nevertheless curious about what has done relatively well so far, here I will detail the performance of the virtual mutual fund I've set up for the Healthcare sector on the Marketocracy web site. Orange line in the chart below shows how my Healthcare Fund has performed relative to the m100 (a collective Marketocracy fund that uses picks from the top 100 members), S&P 500, Dow Jones Index, and Nasdaq. [More...]

Periodicals Wrap-Up for Tuesday, July 22nd

Tue, 22 Jul 2008 14:23:00 GMT

The books of Fannie Mae (FNM) and Freddie Mac (FRE) are being examined by the Federal Reserve and the Office of the Comptroller of the Currency to review their financial condition, according to the Wall Street Journal[More...]

Periodicals Wrap-Up for Tuesday, June 24th

Tue, 24 Jun 2008 14:06:01 GMT

The Wall Street Journal’s “The Game” column speculates that one of the results of the Bear Stearns crash could be the push of investment banks and commercial ones closer together, which could result in better handling of volatility with more stability.[More...]

Hedge Fund Masters 2008...Everyone Loves Qualcomm

Mon, 25 Feb 2008 17:41:21 GMT

Feeling a little contrarian today? Seth Klarman is, and he is buying some beaten down SLM with a full third of his portfolio. . .The 13Fs are arriving and below I update the two tracking portfolios.(For background on this approach, check out

"I don't know that it's all that unusual," said Jeff Aberdeen, controller of Commerce Bancshares Inc., which owns Commerce Bank.

: iStockAnalyst.com Symbols Feed

15 Stocks Having ATough Quarter But Worth A Look

Q2 Growth Report - Part 1

Earnings Season Is Over - Who Were The Growth Leaders?

Quest Diagnostics (NYSE:DGX): Added To Conviction Sell List At Goldman Sachs

Obama-Care Focused on Preventive Medicine

Virtual Funds: Healthcare Fund's Ranking/Performance In Q3 '08 And Overall

Periodicals Wrap-Up for Tuesday, July 22nd

Periodicals Wrap-Up for Tuesday, June 24th

Hedge Fund Masters 2008...Everyone Loves Qualcomm

New Test for Medtox Scientific: As Hiring Has Slowed, Drug Testing Firm Medtox Has Branched Out into Clinical Laboratory Services in the Twin Cities.

LabCorp Has a Good Quarter: Excluding Restructuring Costs, Profits Rise 11% in the 3 Months Ending Sept. 30

Health Discovery Corporation Appoints Tom Gallagher, Former Wall Street Attorney& a Vice President at Goldman, Sachs & Co., to Head the Company's Global Intellectual Property Strategies

Health Discovery Corporation Announces Additional Issued Patents and Notices of Allowance to Its Intellectual Property Portfolio

Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index ; Company Again Named to Both World and North American Indexes

Focus Diagnostics Launches 2009 H1N1 Flu Test Kit to Commercial Laboratories in the U.S.

Integrity Media: A Rise in Revenue

Quest Diagnostics Declares Quarterly Cash Dividend

SmallCapSentinel.com: Report On Diagnostic Imaging Company Released

FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business

Quest Diagnostics Reports Strong Performance in Second Quarter 2009 ; - Total Revenues of $1.9 Billion, Up 3.5%;; - Diluted Earnings of $1.00 Per Share, Up 20%;; - 2009 EPS Outlook Increased to Between $3.70 and $3.80

Quest Diagnostics Reports Strong Performance in Second Quarter 2009

Form 4 Miller Joan Elizabeth For: Nov 06 (10K)

Form 4 Simmons Wayne R. For: Nov 04 (10K)

Form 4 Miller Joan Elizabeth For: Nov 04 (10K)

Form 4 QUEST DIAGNOSTICS INC For: Oct 23 Filed by: Simmons Wayne R. (10K)

Form 4 QUEST DIAGNOSTICS INC For: Oct 23 Filed by: BONGIORNO THOMAS F (10K)

Form 4 Miller Joan Elizabeth For: Aug 20 (10K)

Form 4 Miller Joan Elizabeth For: Aug 17 (10K)

Form 4 QUEST DIAGNOSTICS INC For: Aug 13 Filed by: MOHAPATRA SURYA N (10K)

Form 4 QUEST DIAGNOSTICS INC For: Aug 03 Filed by: BUEHLER WILLIAM F (10K)

Form 4 QUEST DIAGNOSTICS INC For: Jul 29 Filed by: PREVOZNIK MICHAEL E (10K)